Cannibalization, Intense Competition Both Enormous Roadblocks for Chipotle Recovery

Shares of fast casual chain Chipotle Mexican Grill (CMG) are holding above $400 per share recently as investors cling to hopes that a full recovery is taking shape after e coli outbreaks halted the company's impressive growth trajectory. Unfortunately for CMG bulls, the numbers do not seem to support that thesis.

Same-store sales have gotten back into positive territory in 2017, as the initial health issues from late 2015 are being lapped on the calendar, but overall sales volumes have not seen any improvement. Below are charts showing same-store sales (promising) and average unit volumes (illuminating) for CMG: 

cmg.jpg

Even though same-store sales improved in Q4 2016 vs Q4 2015, total sales volumes continue to decline both year-over-year and sequentially. The year-over-year drops will likely continue for at least the first half of 2017, whereas the sequential declines will likely end very soon. The problem is that CMG is still planning to grow total units at a healthy clip (nearly 10% annually) and new units are only bringing in roughly $1.5 million each in annual revenue (~75% of mature units). This is most likely due to cannibalization from existing units, which limits volumes from new locations (proximity between units shrinks as more are opened).

Chipotle's stock was a huge winner before the e coli issues due to lower build-out costs, high unit volumes, and profit margins that were the envy of peers. As the company continues to grow, the numbers will work against them and make it very difficult to regain their former financial glory ($2.5 million in average unit sales and four-wall margins of 27% at their peak). Without those kinds of metrics, the stock price looks richly priced at current levels with an equity market value well north of two times annual revenue. Buyer beware.

Full Disclosure: No position in CMG at the time of writing, but positions may change at any time

Beware of Seemingly Reasonable P/E's on Growth Tech Companies

Pop Quiz:

Do all technology companies expense stock-based compensation in their financial statements? Perhaps more importantly, do sell-side analysts include such expenses in their quarterly earnings estimates, on which every quarterly report is judged by Wall Street?

Given that stock-based comp has been a hot button accounting issue for a couple of decades, and the chief accounting rule board (FASB) required GAAP financial statements to include such expenses way back in 2004, I suspect that most investors are not really paying attention to the issue anymore.

Since I am a value-oriented investor, most of my investments are outside of the high growth tech sector, where most of the stock-based compensation resides. Nonetheless, a few months ago I wanted to dig a little digging because I did not understand why market commentators in the financial media were seeming to understate the P/E ratio of the S&P 500. I have been closely watching S&P 500 index earnings for most of my career, so it struck me as puzzling when people on CNBC would claim something like "The S&P 500 trades at 17 times earnings, which is only modestly above historical averages." In fact, the numbers I saw on the actual Standard and Poor's web site showed the P/E to be more like 19 or 20x. Given that the historical average is around 15x, there is a big difference between 17x and 20x. So what the heck is going on?

It turns out that there is a large financial data aggregation company called FactSet, which supplies many investors with earnings data on the S&P 500. You can find their earnings data directly on their web site. After reading through it I realized that FactSet was showing higher earnings levels for the S&P 500 (which equates to lower P/E ratios by definition), and that is where the market commentators were getting their valuation information. For instance, the current FactSet report shows that calendar year 2016 earnings for the S&P 500 are projected at $119, which gives the index a trailing P/E of 19.3x. However, the S&P web site shows a figure of $109, which equates to a trailing P/E of 21.1x. Investing is hard enough, but now we can't even agree on what earnings are? Maybe I'm making a big deal out of nothing, but this is frustrating.

The logical question I needed to answer was what accounted for the gap in earnings tallies. If earnings really were 9% above the level I thought, my view of the S&P 500's valuation would undoubtedly change. I was shocked when I learned the answer.

It turns out that FactSet's earnings data does not represent the actual earnings reported by the companies comprising the S&P 500, which is what the figures on the S&P web site show. Instead, FactSet uses the reported earnings that match up most closely with the Wall Street's analysts' quarterly forecasts. Put another way, if the analyst community excludes certain items from their earnings estimates, FactSet will adjust a company's actual reported earnings to reflect those adjustments (for an apples to apples comparison to the Wall Street estimate) and those earnings figure are used when they tell the investment community what the earnings for the index actually are. If this sounds bizarre to you, it should.

Having followed the market for my entire adult life (and all my teenage years too), I immediately knew what accounted for much of the gap between these earnings estimates. Most technology companies still to this day report non-GAAP earnings results right along side GAAP figures in their earnings reports. For reasons I don't understand (since the issue of whether stock compensation is an actual expense was resolved years ago), the analyst community excludes these expenses in their numbers, so when a tech company reports earnings, the non-GAAP number is comparable to the analyst estimate. As such, the non-GAAP number is incorporated into FactSet's data. So whenever a stock market commentator quotes the FactSet's version of the index's P/E ratio, they are inherently ignoring billions of dollars of employee compensation that is being paid out in shares instead of cash.

To illustrate this point, Consider Google/Alphabet's fourth quarter earnings report from last night. The analyst estimate was $9.44 per share and Google reported $9.36 per share. So today's media headlines say that the company "missed estimates." If you read the financial statements carefully you will see that Google's GAAP earnings were actually $7.56 per share. The non-GAAP earnings figure, which is the ones that is reported on because that is how the analysts do their projections, was a stunning 24% higher than the actual earnings under GAAP accounting rules.

You can probably guess why there was such a large gap. During the fourth quarter alone, Google incurred stock-based compensation expense of... $1.846 billion! Multiply that by four and Google's run-rate for stock compensation is $7.4 billion per year! That is $7.4 billion of actual expenses that are being excluded from FactSet's earnings tally, and that is just from one company (albeit a big one) in the S&P 500 index.

So how does this impact investment decisions? Well, there are many people that look at Google and see an $850 stock price and $34.40 earnings for 2016 and conclude that the stock is quite reasonably priced given the company's growth rate, at less than 25 times trailing earnings (850/34.40=24.7). Of course, the actual P/E is 30.5x because when you add back stock-based comp Google's earnings per share decline from $34.40 to $27.85.

The valuation differentials get even larger when you consider younger, smaller technology companies because these firms seem to be addicted to stock-based compensation. Google pays out a lot in stock, but even that $7.4 billion figure is only 7% of the company's revenue. Paying out 7% of sales as stock compensation is indeed a very large figure, but other tech companies dole out far more.

I looked at some other fairly large ($5-50 billion market values) tech firms and the numbers are staggering. During the first three quarters of calendar 2016, Salesforce.com (CRM) paid out 9% of revenue in SBC, but that seemed quite low compared with some others. Zillow (ZG): 13%. ServiceNow (NOW): 23%. Workday (WDAY): 24%. Twitter (TWTR): 26%. Can you believe that some tech companies pay a quarter of revenue in stock-based compensation? Not total compensation, just the stock portion!

Importantly for investors, these companies are getting very large valuations on Wall Street. In fact, those five tech companies have current equity market values that cumulatively exceed $100 billion. I wonder if investors might view them a little less favorably if they realized they might be less profitable than the appear on the surface.

For me, the takeaway from all of this is that all investors should dig deeper into valuations in general. Don't just take figure you hear on CNBC or read in press releases as gospel. Just because a web site says a company has earnings of X or a P/E ratio of Y does not mean there isn't more to the story.

Dow 20,000: Just A Number

How about that? Dow 20,000! What a hugely important milestone! Right? Well, not really.

Sure it will make for a good front page story in USA Today tomorrow, and those few humans who are still needed on the trading floor of the New York Stock Exchange (they've been largely replaced by machines) will unpack the Dow 20K hats for sure, but Dow 20,000 is no more important than Dow 18,763.

When the Dow Jones Industrial Average is this high, we actually would expect new milestones to be reached on a very regular basis. An average stock market year (+10%) would actually see us break through another 1,000 point level every six months. Even if we stretch the milestone interval to 5,000 points, it will only take two and a half years on average.

In fact, it only took 18 years from 10,000 to 20,000. That might sound like a long time for the index to double (it's only a 4% average return during that time), but that period includes the massive dot-com market collapse of 2000-2002, as well as the Great Recession of 2008-2009.

Here is a calendar breakdown of Dow Jones milestones:

dow20k.png

As you can see, every milestone from Dow 3,000 through Dow 20,000 has occurred since the 1990's. Dow 1,000 --- now that was a milestone... it took 76 years from the index's creation in 1896 for it to pierce the 1,000 level!

Also of note is how the Dow itself has become less and less relevant over time for investors. Most of us use the S&P 500 index since it represents more broadly diversified group of public companies, versus just 30 for the Dow. This is also because the S&P 500 is value-weighted, meaning that a company worth $10 billion comprised twice as much of the index as a $5 billion company.

The Dow, on the other hand, is share price-weighted. So while Bank of America (market value $235 billion) is ~2.5 times larger than Goldman Sachs (market value ~$95 billion), it actually makes up far less of the Dow's composition than Goldman does. In fact, BofA's share price is only 1/10th that of Goldman, so a $1 increase in GS stock (which is a gain of 0.4%) adds the same amount of points to the Dow as a $1 increase in BofA stock (a gain of 4%) does. It's really a bizarre methodology.

Despite all of that, I'm glad we are getting 20K out of the way so we can stop hearing about it. That is, of course, until we hit Dow 25K, which history suggests is most likely to happen in just a few years. 

Healthcare Stocks Look Poised To Rebound In 2017

Perhaps one of the more surprising stock market trends post-election has been the relative inability for the healthcare sector to get back on track after taking a beating during the campaign season. With government deregulation on the way, as well as a bipartisan bill having passed Congress late in 2016 that will serve to loosen the FDA drug approval process, rational minds might have expected healthcare stocks to stage a large rally, much has been the case with banking stocks (same thesis; rolling back the regulations put in place post-recession).

We have seen a bit of a pickup in recent days, but after an initial one-day surge on November 9th, healthcare stocks have been lagging generally. I fully expect that 2017 will be a much better year for the sector. Abusive drug price increases will surely still get the attention on lawmakers, but that practice should come to somewhat of a halt now that the industry has seen what can happen to the likes of Valeant (VRX).

While investors will have to temper their growth rate expectations for pharmaceutical-related companies, the fundamental demand story should remain intact longer term. The strong companies should have no trouble churning out consistent sales and strong cash flow. Doing so will prove to investors just how resilient the industry can be, and should result in more normal valuations for most players in the sector.

To give you an example of how strange some of the price action has been in these names, consider one that I have been accumulating recently, both personally and for clients: CVS Health (CVS). This leading healthcare name has seen its share price take a stunning downward turn, from over $100 to as low as $70 per share. It's hovering around $80 currently.

cvs.png

CVS is not some small drug company with a few products that has grown by dramatically increasing prices. We are talking about a blue-chip franchise with leading positions in both retail drugstores and pharmacy benefit management. The historical record of shareholder value creation is impressive. From a long-term demographic perspective, CVS stands to benefit greatly from drug innovations and an aging population.

And yet somehow the stock is currently fetching just 14 times annual earnings, a whopping 30% discount to the S&P 500 index. With overall valuations in the market in the upper band of the historically normal range, CVS looks like quite a bargain, even as the sector has been a focal point for criticism. While stocks like this have hurt investor performance lately, myself included, I see little reason to think 2017 cannot be the start of a healing process for an excellent American company like CVS Health.